Novo Nordisk drags competitor to court over Saxenda copies
According to Novo Nordisk, a firm based in India has made a copy of its obesity drug, Saxenda. Novo is now fighting to get the copy off the market in a US court.
by marketwire, translated by catherine brett
Novo Nordisk has summoned Orbicular Pharmaceutical Technologies before a court in Delaware in the US to block the launch of a generic copy of its obesity drug, Saxenda, Bloomberg News reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Novo Nordisk and Leo Pharma seek permission to use oil
For subscribers
